GlassScriptPhysician profile
Konstantin Walmsley
NPI 1730156456
$30,599.92
in general payments reported to CMS, 2019-2025
42 companies · $6,954 in 2025
The $6,954 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,295 · 2020: $446 · 2021: $2,985 · 2022: $6,613 · 2023: $4,041 · 2024: $5,266 · 2025: $6,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,840 · Travel and Lodging: $7,411 · Consulting Fee: $1,000 · Education: $8.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,840.31 |
| Travel and Lodging | $7,411.44 |
| Consulting Fee | $1,000.00 |
| Education | $8.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $8,728.38 | 2021-2025 | Urolift, Barrigel |
| Axonics, INC. | $5,920.85 | 2021-2024 | Axonics, Bulkamid |
| Neotract INC. | $3,271.31 | 2019-2020 | |
| Medtronic, INC. | $1,738.53 | 2023-2025 | Interstim, Altaviva, Nuro |
| Valencia Technologies Corporation | $1,534.92 | 2023-2025 | Ecoin Device Kit |
| Janssen Biotech, INC. | $1,263.70 | 2019-2025 | Erleada, Akeega |
| Procept Biorobotics Corporation | $1,163.17 | 2020-2025 | Aquabeam System |
| Telix Pharmaceuticals | $1,039.93 | 2024 | |
| Boston Scientific Corporation | $871.70 | 2020-2025 | General - Female Sui, Axonics, Rezum Generator |
| Bayer Healthcare Pharmaceuticals INC. | $684.83 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $386.36 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $315.47 | 2019-2024 | Xtandi |
| Myriad Genetic Laboratories, INC. | $313.40 | 2023 | Myrisk |
| Janssen Scientific Affairs, LLC | $267.90 | 2025 | Erleada |
| Ferring Pharmaceuticals INC. | $249.65 | 2019-2025 | Adstiladrin |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $238.38 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $229.73 | 2023-2025 | Gemtesa |
| Urogen Pharma, INC. | $208.23 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $192.38 | 2021-2023 | Xiaflex |
| Olympus America INC. | $192.32 | 2021-2025 | Itind System |
| Immunitybio, INC. | $174.92 | 2024-2025 | |
| Profound Medical Corp. | $161.26 | 2025 | Tulsa-Pro |
| Progenics Pharmaceuticals, INC. | $146.44 | 2022-2025 | |
| Pfizer INC. | $142.81 | 2019-2025 | |
| Conmed Corporation | $130.39 | 2022 | |
| Baxter Healthcare | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $120.54 | 2024 | Lynparza |
| Coloplast Corp | $116.31 | 2019-2020 | |
| Tolmar, INC. | $103.06 | 2024-2025 | Eligard, Jatenzo |
| Koelis INC. | $98.85 | 2021 | |
| Blue Earth Diagnostics | $97.58 | 2019 | |
| 180 Medical, INC. | $63.81 | 2023-2025 | |
| Tolmar Pharmaceuticals, INC. | $56.21 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $50.57 | 2025 | Azmiro |
| Abbvie INC. | $43.10 | 2019-2025 | |
| Allergan, INC. | $40.42 | 2019-2022 | |
| Myovant Sciences INC. | $31.82 | 2021 | |
| Avyxa Pharma, LLC | $25.28 | 2025 | |
| Accord Healthcare, INC. | $21.24 | 2024 | |
| Mission Pharmacal Company | $16.03 | 2019 | |
| Urovant Sciences INC | $14.58 | 2021 | |
| Escala Medical INC. | $8.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Konstantin Walmsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.